Search research articles
Contact Us
Filters
Showing results (231-240 of 254) with videos related to
Page
of 26
Sort By:
Kidney International. Supplement
|
October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria
Nagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
Nature Medicine
|
August 6, 2024
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
Diabetes Care
|
December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Avivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
Diabetologia
|
February 21, 2021
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
Michelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 19, 2020
Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood
Aya Bardugo, Cole D Bendor, Inbar Zucker, et al.
European Journal of Heart Failure
|
December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Diabetes, Obesity & Metabolism
|
April 3, 2020
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
Avivit Cahn, Itamar Raz, Marc Bonaca, et al.
JAMA Cardiology
|
March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial
Thomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology
|
March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Meir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 254) with videos related to
Sort By:
Page
of 26
Kidney International. Supplement
|
October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria
Nagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
Nature Medicine
|
August 6, 2024
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
Diabetes Care
|
December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Avivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
Diabetologia
|
February 21, 2021
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
Michelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 19, 2020
Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood
Aya Bardugo, Cole D Bendor, Inbar Zucker, et al.
European Journal of Heart Failure
|
December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Circulation
|
April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Diabetes, Obesity & Metabolism
|
April 3, 2020
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
Avivit Cahn, Itamar Raz, Marc Bonaca, et al.
JAMA Cardiology
|
March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial
Thomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology
|
March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Meir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Page
of 26